cvot tirzepatide Zain Khalpey, MD, PhD, FACS on X: "SURPASS-CVOT shows delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize tirzepatide cardiovascular outcomes An Observational
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




























